HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

P2Y12-receptor-inhibiting antiplatelet strategies in acute coronary syndromes.

Abstract
Antiplatelet therapy in acute coronary syndromes is essential for preventing stent thrombosis and for reducing major adverse cardiovascular events. Treatment strategy has changed over the last years by frequent use of more active agents inhibiting the ADP mediated activation of platelets instead of clopidogrel, such as prasugrel and ticagrelor. Compared to clopidogrel these modern antiplatelet drugs showed a significant reduction of efficacy endpoints as well as an acceptable safety profile in large multicenter randomized trials (TRITON TIMI 38, PLATO). Going in with higher efficacy a generally higher bleeding risk of prasugrel could be reduced by optimizing the maintenance dose in elderly and underweight patients (TRILOGY-ACS). However even prasugrel and ticagrelor have shown a delayed onset of action in special patient populations (e.g. STEMI) suggesting that the optimal ADP inhibitor has not been found yet. Results of the CHAMPION PHOENIX trial indicate that cangrelor, an intravenous agent, might fulfill these high expectations of an ideal platelet inhibitor in the first hours of an ACS in special patient cohorts. This review summarizes the results of most important clinical studies investigating the novel P2Y12 receptor inhibiting antiplatelet drugs.
AuthorsT Höchtl, K Huber
JournalHamostaseologie (Hamostaseologie) Vol. 34 Issue 1 Pg. 20-8 ( 2014) ISSN: 2567-5761 [Electronic] Germany
PMID24220294 (Publication Type: Journal Article, Review)
Chemical References
  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
Topics
  • Acute Coronary Syndrome (drug therapy)
  • Dose-Response Relationship, Drug
  • Drug Design
  • Evidence-Based Medicine
  • Hemorrhage (chemically induced, prevention & control)
  • Humans
  • Platelet Aggregation Inhibitors (administration & dosage, adverse effects, classification)
  • Purinergic P2Y Receptor Antagonists (administration & dosage, adverse effects, classification)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: